Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $518.03, for a total value of $4,921,285.00. Following the completion of the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at approximately $67,343.90. The trade was a 98.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Price Performance

NASDAQ:UTHR traded up $6.64 during mid-day trading on Tuesday, reaching $535.81. The stock had a trading volume of 785,658 shares, compared to its average volume of 403,486. The stock has a market cap of $23.48 billion, a P/E ratio of 19.20, a PEG ratio of 1.72 and a beta of 0.84. The business’s 50 day moving average is $483.03 and its 200 day moving average is $455.82. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $548.12.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company earned $6.19 earnings per share. Equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Corient Private Wealth LLC boosted its holdings in United Therapeutics by 13.5% during the fourth quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company’s stock valued at $9,379,000 after acquiring an additional 2,289 shares during the period. Rehmann Capital Advisory Group grew its position in shares of United Therapeutics by 9.8% in the fourth quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock valued at $1,767,000 after purchasing an additional 324 shares during the last quarter. Tobam increased its stake in shares of United Therapeutics by 28.9% in the fourth quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock worth $4,803,000 after purchasing an additional 2,211 shares during the period. Wick Capital Partners LLC acquired a new position in shares of United Therapeutics during the 4th quarter worth about $297,000. Finally, Mishpacha Holdings Corp acquired a new position in shares of United Therapeutics during the 4th quarter worth about $487,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on UTHR. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. HC Wainwright boosted their price target on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Royal Bank Of Canada increased their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Finally, Bank of America restated a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $539.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.